Clinical Trial Update: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating TJ011133 as monotherapy and in combination with azacitidine in AML or MDS has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• TJ011133

Snippet

Sponsor: TJ Biopharma Co., Ltd. | Conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | Phase 1, Phase 2 | Status: COMPLETED